Statements (41)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Protalix_Biotherapeutics_acquired_by_a_subsidiary_of_Teva_Pharmaceutical_Industries
|
| gptkbp:CEO |
gptkb:Dror_Bashan
|
| gptkbp:clinicalTrials |
gptkb:Gaucher_disease
Phase III clinical trials aims to improve clinical outcomes for patients conducts trials in various phases develops therapeutic products for patients ongoing clinical research programs submitted biologics license application for products |
| gptkbp:collaboratesWith |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:collaborations |
collaboration_with_the_National_Institutes_of_Health
|
| gptkbp:communityEngagement |
engages with patient communities
|
| gptkbp:communityPartnerships |
partnership with universities
|
| gptkbp:develops |
enzyme replacement therapies
|
| gptkbp:financials |
publishes quarterly financial reports
|
| gptkbp:focusesOn |
biopharmaceuticals
|
| gptkbp:founded |
2001
|
| gptkbp:globalPresence |
operates globally
|
| gptkbp:hasPrograms |
has a scientific advisory board
|
| gptkbp:headquarters |
Carmiel, Israel
|
| gptkbp:historicalResearch |
engages in collaborative research projects
|
| https://www.w3.org/2000/01/rdf-schema#label |
Protalix Biotherapeutics
|
| gptkbp:investmentFocus |
institutional investors
maintains investor relations activities raised funds through public offerings |
| gptkbp:market |
approximately $100 million
FDA_approval_for_Elelyso_in_2012 |
| gptkbp:notableEvent |
Elelyso
|
| gptkbp:partnerships |
gptkb:Pfizer
has multiple strategic partnerships |
| gptkbp:patentCitation |
holds multiple patents
|
| gptkbp:productLine |
pipeline includes multiple candidates
|
| gptkbp:products |
focuses on product development in biotechnology.
|
| gptkbp:regulatoryCompliance |
received orphan drug designation
|
| gptkbp:research |
receives funding for research initiatives
|
| gptkbp:research_areas |
metabolic disorders
|
| gptkbp:researchFocus |
rare diseases
|
| gptkbp:technology |
plant cell culture
|
| gptkbp:tradedOn |
gptkb:NYSE_American
|
| gptkbp:website |
www.protalix.com
|